Categories Analysis, Earnings, Technology

Earnings preview: Has Garmin stayed fit through the second quarter?

Garmin Ltd. (GRMN) is scheduled to report its second-quarter 2018 earnings results on August 1. For the first quarter, the sports watch-maker reported an 11% increase in sales and a 31% increase in pro forma EPS. Sales growth was helped by strength across all divisions except auto, with the highest improvement seen in the outdoor division.

According to a report by Markets Insider, for the second quarter, analysts expect Garmin to report sales of over $843 million, which would reflect an increase of 3% over last year. Earnings are expected to come in at $0.86 per share.

Last quarter Garmin had guided for full-year 2018 revenues of $3.2 billion and pro forma EPS of $3.05. Analysts expect EPS to come in at $3.13 and revenues to total $3.23 billion.

During the first quarter, Garmin saw significant growth in the outdoor and fitness segments with sales increases of 24% and 20% respectively. The company continues to see opportunities for wearables in both these segments. The wearables market is seeing good growth and Garmin, along with Fitbit (FIT), is said to be giving tough competition to Apple (AAPL).

Garmin sees opportunities for wearables in the outdoor and fitness segments

Earlier this month, it was reported that the imposition of tariffs on $200 billion of Chinese goods was likely to hurt smartwatches and wearables. While Fitbit was named as a possible victim of the tariff war, it is not clear whether Garmin would be impacted in any way. This might be an area to watch out for.

Meanwhile, Garmin’s co-founder Min Kao has sold over 4 million shares, worth more than $260 million, from his stake in the company over the past five months.

Gauging by the strength in the wearables market, Garmin is likely to report positive results for its second quarter. The strength in the outdoor and fitness devices markets could prove to be beneficial for the company this quarter too.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top